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ABSTRACT
On December 17, 2018, the North American branch of the International Life Sciences Institute (ILSI North America)
convened a workshop “Can We Begin to Define a Healthy Gut Microbiome Through Quantifiable Characteristics?” with
>40 invited academic, government, and industry experts inWashington, DC. Theworkshop objectiveswere to 1) develop
a collective expert assessment of the state of the evidence on the human gut microbiome and associated human health
benefits, 2) see if there was sufficient evidence to establish measurable gut microbiome characteristics that could serve
as indicators of “health,” 3) identify short- and long-term research needs to fully characterize healthy gut microbiome–
host relationships, and 4) publish the findings. Conclusions were as follows: 1) mechanistic links of specific changes
in gut microbiome structure with function or markers of human health are not yet established; 2) it is not established
if dysbiosis is a cause, consequence, or both of changes in human gut epithelial function and disease; 3) microbiome
communities are highly individualized, show a high degree of interindividual variation to perturbation, and tend to be
stable over years; 4) the complexity ofmicrobiome-host interactions requires a comprehensive,multidisciplinary research
agenda to elucidate relationships between gut microbiome and host health; 5) biomarkers and/or surrogate indicators
of host function and pathogenic processes based on the microbiome need to be determined and validated, along with
normal ranges, using approaches similar to those used to establish biomarkers and/or surrogate indicators based on
host metabolic phenotypes; 6) future studies measuring responses to an exposure or intervention need to combine
validatedmicrobiome-related biomarkers and/or surrogate indicators withmultiomics characterization of themicrobiome;
and 7) because static genetic sampling misses important short- and long-term microbiome-related dynamic changes to
host health, future studies must be powered to account for inter- and intraindividual variation and should use repeated
measures within individuals. J Nutr 2019;149:1882–1895.
Keywords: microbiome, microbiota, prebiotic, probiotic, dietary fiber, biomarker, surrogate indicator, dysbiosis,
human health
Introduction
Microbial colonization of the human body begins postpartum
(1–4) and proceeds in an incremental manner from infancy
to adulthood, with the largest microbial community being
found in the distal regions of the adult human gastrointestinal
tract (5). Intestinal colonization occurs during infanthood
(5–7) and is affected by mode of delivery (8, 9), diet
(10–12), probiotic supplementation (13, 14), antibiotic use
(15, 16), and possibly maternal microbiome during pregnancy
(4, 17). The resilience of a microbiota—that is, the capacity
to return to an equilibrium state in response to chemical (e.g.,
diet, antibiotic), physical (e.g., changes in rate of intestinal
passage, pH), or microbial (e.g., probiotic supplementation,
fecal transplants) perturbations—is a metric that seems to
be associated with higher microbial diversity (18). Numerous
published reports have described associations between altered
microbiota composition and various diseases; however, there
have been few consistent changes in microbiota stability,
resilience, or diversity associated with a given disease across
multiple cohorts.
Copyright C© American Society for Nutrition 2019. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Manuscript received April 26, 2019. Initial review completed May 22, 2019. Revision accepted June 11, 2019.
First published online August 2, 2019; doi: https://doi.org/10.1093/jn/nxz154.1882
Elucidation of other characteristics of a microbiome pre-
dictive of health would provide a target for interventions
and microbial modifications in generally healthy populations
and individuals exhibiting disrupted microbiota and associated
diseases (19). Validated indicators for which a scientific
consensus could be achieved could contribute to a framework
to guide policymakers and regulators on marketing and product
claims pertaining to a “healthy human microbiome.” This
article summarizes the state of the science pertaining to the
human gut microbiome and associated health benefits and
identifies research gaps and opportunities.
State of the Evidence
In 2012, the International Life Sciences Institute (ILSI)
North American Microbiome Committee commissioned a
review on the question “what constitutes a healthy human
gut microbiome” (19) that came to the following conclusions:
1) a healthy microbiome cannot be defined by a single
idealized community composition, 2) a healthy microbiome is
more resistant and resilient to disruption, 3) certain microbial
distributions may increase susceptibility to infection and
disease, and 4) it is unknown if dysbiosis, an imbalance in the
types of microorganisms present in a given microbiota, is a
cause or consequence of disease. For this article, we revisited the
central question and evaluated whether the state of the evidence
has changed substantially in the past 6 y.
Biological Considerations in Defining a
Healthy Gut Microbiome
The gut microbiota clearly influences the health of its host.
It provides crucial benefits in the form of immune system
development, prevention of infections, nutrient acquisition, and
perhaps even brain and nervous system functionality (20). In
addition, the microbiome does clearly play a causal role in
the development of pathologies in animal models of human
disease, such as obesity (and associated pathologies), autoim-
mune diseases, and neurological diseases (21–27). In humans,
causality is much harder to establish, but environmental factors
known to disrupt microbiome assembly [e.g., route of birth
delivery (8, 9, 28), formula vs. breastfeeding (28, 29), and early
antibiotics (30)] are linked with disease risk in epidemiological
studies (31, 32). In addition, human diseases are often associated
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with a “dysbiosis” of the gut microbiota, meaning an altered
composition or functionality compared with healthy controls.
However, dysbiotic patterns are context and disease specific
and often not consistently detected among different studies. In
addition, for most diseases, it is unclear if dysbioses are the
cause or the consequence of disease, and molecular mechanisms
by which altered microbiomes cause disease are lacking (27).
Due to these complications, it is extremely difficult to define
what constitutes a healthy microbiome. Below we discuss the
ecological characteristics of the gut microbiome in early life and
in adults, as well as the associations that have been associated
with health.
Infant Microbiome Insights
The composition of the human gut microbiota changes
dramatically during the first few years of life (6, 33) and then
remains relatively stable (34). Microbial diversity in an infant
gut increases over time (6, 8, 33), and the assembly process is
affected by delivery mode, with the gut microbiota of infants
born by caesarian section being less diverse during the first
2 y of life than those born vaginally (8, 9). Development of
intestinal microbiota in infants is influenced by feeding method
(breastfeeding vs. formula) (10, 12), use of probiotics and
antibiotics (15, 30), and the introduction of complex dietary
substrates during weaning (5, 35). Although these deterministic
factors have a clear, measurable impact on microbiome
composition, community assembly is also driven by stochastic
(nonpredictable) ecological processes (36, 37). Experimental
studies in a mouse model where host and environmental
factors are strictly controlled find early-life colonization order
influences the outcome of the community assembly through
priority effects (38). Since the order of arrival of early colonizers
is to a large degree random (e.g., in infants born by caesarian
section) and largely influenced by life events such as antibiotics
that can also not be predicted, stochastic ecological processes
might account for the >70% of the interindividual variation of
the human microbiome that is currently unexplained (39, 40).
Differences in the trajectory of early-life microbiome assem-
bly during the first years of life may have long-term effects
on not only microbiome ecology but also the development of
host gastrointestinal and associated lymphatic tissues, which
would determine the risk of immune-mediated diseases (9, 41).
Early-life events, including mode of delivery and type of feeding,
siblings, and sex, shape the developing gut microbiota (28).
The early gut microbiota of breastfed, vaginal-born infants
is dominated by Bifidobacterium and Bacteroides species,
which have evolved with humans and have specialized in the
utilization of human milk oligosaccharides (42). These genera
could therefore be considered characteristic for a healthy infant
microbiota, and they are greatly reduced through cesarean
sections and formula feeding (8, 9). However, in the absence of
clinical data, there is insufficient evidence to define a universal
standard for intestinal colonization and development of the
infant microbiome (5), and this report will focus on defining
the role of a healthy gut microbiome in adults.
Adult Microbiome Insights
The gut microbiome is a remarkably stable microbial commu-
nity in healthy adults composed of highly adapted microbial
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FIGURE 1 Long-term persistence or nonpersistence of an orally administered bacterial strain, AH1206, in 2 sets of individuals. Reproduced
with permission from Maldonado-Gómez et al. (67).
species (43, 44) and shaped more by environment than host
genetics (39, 45). Nongenetic and genetic factors each account
for ∼10% of the variation in gut microbiota, whereas effects
of specific environmental factors (diet, medication, specific
genes, etc.) account for ∼20% (39, 40), making the majority
of interindividual variation in the human gut microbiota
unexplained. Ecological theory predicts that such unpredictable
variation is driven by stochastic elements in the ecological
processes that shape ecosystems (38).
High microbiota diversity seems to be associated with health
and temporal stability (33, 34), and a dynamic loss of diversity
may be prognostic of increased disease risk (34, 46). A physi-
cally inactive lifestyle and the consumption of a diet that is high
in refined carbohydrate and salt and low in dietary fiber (47,
48) are associated with a depleted microbiome and increased
prevalence of chronic disease linked to the gut microbiome
(49). When confronted with environmental perturbations—
for example, dietary interventions [isocaloric diets differing in
fat and carbohydrate content (50) or 4 probiotic multispecies
provided at breakfast in a capsule, low-lactose yogurt, or low-
fat semihard cheese (51)] or antibiotics [500 mg ciprofloxacin
twice a day (52)]—the gut microbiome changes (50–52).
Overall, the composition of the diet influences the metabolic
output of the microbiota (50), with unhealthier, Western-style
diets rich in saturated fat and meat and low in fiber, leading
to metabolite profiles likely to be detrimental to health (50,
53). Shifts in the composition and metabolic signatures of an
individual’s gut microbiome are seen in response to acute dietary
[e.g., addition of resistant starch or fruits, vegetables, and
legumes (54–56)] and medical interventions [e.g., antibiotics
(52)]. Microbial diversity is negatively correlated with stool
consistency and stool frequency, and stool consistency was
shown to make the largest contribution to interindividual fecal
microbiota variation, although its overall contribution to the
total variation is still small (57, 58). Longer colonic transit times
have been positively correlated with gut microbiota diversity
and richness, a shift in microbial metabolism from carbohydrate
fermentation to protein catabolism, and higher urinary levels
of potentially deleterious protein-derived compounds (59). If
perturbations are a consequence of dietary change (60–62), the
microbiome essentially reverts to its initial composition due to
its resilience (56). If more severe (e.g., through repeated courses
of antibiotics), the repair of the microbiome is incomplete, and
members are lost (52, 63, 64).
The gut microbiome is altered in various diseases, a state
often referred to as dysbiosis (65). Redressing such alterations
through strategies such as fecal microbiota transplantation
(FMT), probiotics, or live biotherapeutics may shape the
development and function of the gut, its associated immune
system, and other organs. Establishing persistent long-term
changes in taxonomic structure to affect the long-term health
of the host may be possible with FMTs and probiotics (66,
67) (Figure 1). However, a substantial knowledge gap exists
about what constitutes a healthy microbiome and if such a
microbiome can even be defined, as a definition may be both
subject and context (e.g., disease) dependent. Most important,
it is unclear if dysbioses are the cause of the disease or just a
consequence (27).
There is evidence that the microbiome is affected by
many characteristics of the host, including ethnicity, region
of habitation, geography, and/or socioeconomic status (45,
46, 68, 69). Cross-population surveys find regional differences
in susceptibility and prevalence of disease may be explained
by differences in gastrointestinal microbiota (45). Individuals
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living in neighborhoods with higher socioeconomic status
(SES) exhibit indicators of greater microbiota diversity (vs.
low SES) that do not appear to be a proxy for other
demographic characteristics such as age, sex, self-reported
racial/ethnic heritage, or lifestyle factors such as adiposity,
smoking, or alcohol consumption (70). Unfortunately, alcohol
intake (an exclusion criterium for the healthy controls) was
the only dietary assessment in this study. The Healthy Life
in an Urban Setting (HELIUS) study encompassed ∼25,000
individuals from 6 ethnic groups living in Amsterdam, The
Netherlands, who donated a stool sample (71). Within this
single urban population, ethnic origin of participants was
the strongest determinant of differences in fecal microbiota
composition even after adjustment for dietary and nondietary
factors (68). However, the lack of relationship between diet
and microbiome may reflect the use of a single FFQ with 37
food groups being given to only 5 of 6 ethnic groups and
then truncated into 4 dietary patterns for statistical analysis.
It is possible that the HELIUS ethnic-specific FFQs were used
(72), but distillation of diet composition to 4 patterns is not
an accurate assessment. In a study of 1041 Israeli adults, the
gut microbiota was more strongly influenced by environment
than genetics, with environmental factors accounting for 20%
of the total variance and these characteristics identified as
sources of variance (percentage of total 20% variance): blood
measurements (33%), vegetables (26%), meat products (16%),
fruit (16%), and diet (5%). The dietary, ethnic, physical, and
economic diversity of neighborhoods, urban or rural, makes
the determination of factors causally affecting gut microbiome
diversity and associations with human health elusive. Regional
variation limits the development and application of healthy
microbiome reference ranges (46).
Because of these challenges associated with identification
and characterization of major gut microbiome patterns (73),
enormous ecological gut microbial diversity among healthy
adults (74), and ethnic origins and geographic locations (46, 68),
it will likely prove extremely difficult to define a single, healthy
microbiome.
Dietary Modulation
The health benefits of eating a diet rich in dietary fiber were
recognized in 430 B.C. by Hippocrates (75). Except for its use
as a natural remedy for constipation, dietary fiber was once
considered a negative index of diet quality until low-fiber intake
was associated with large bowel diseases (76). All dietary fiber
definitions around the world include nondigested carbohydrate
(CHO) and lignin inherent in food, and most include nondi-
gestible CHOwhen extracted from edible material, synthesized,
or modified if they have at least 1 demonstrated health benefit
(77). It is now accepted that type, quality, and food origin shape
the gut microbiome and microbiota-host interactions that may
affect host health (78, 79).
A low dietary fiber intake does not support a healthy, diverse
gut microbiome (80, 81) and is associated with degradation of
the colonic mucus barrier on the gut epithelial lining (82, 83),
as well as with production of nitrogen- and sulfur-containing
compounds that are genotoxic and cytotoxic to colonocytes (59,
84–86). Ingestion of dietary fiber sources stimulates microbial
proliferation, produces microbially derived end products [e.g.,
SCFAs and other microbial metabolites (81, 87)], and shifts the
handling of colonic nitrogen by gut microbiota and host (59,
84, 88, 89). Twenty-four-hour urinary excretion of p-cresol, a
urinary toxin, is significantly decreased in healthy subjects after
consuming 10 g of wheat bran daily for 3 wk (89) or 20–30 g
lactulose daily for 4 wk (90).
A dietary prebiotic is defined as “a substrate that is selectively
utilized by host microorganisms conferring a health benefit”
(91, 92), although the requirement of “selectivity” has been
questioned (93). The addition of a prebiotic to the diet
may have health benefits; for example, galactooligosaccharide,
a prebiotic, decreases intestinal permeability (94), improves
laxation when dietary fiber intake is low (95), and may protect
from low-fiber diet-induced colonic mucus deterioration (83,
96). Not all dietary fibers are considered prebiotic (97–99) and
dietary fibers differ in their physicochemical impact within the
colonic ecosystem (85, 100). The ingestion of some prebiotics,
but not all, significantly increases absolute fecal numbers of
Bifidobacterium and the percentage of total fecal microbiota
(89, 101–103). It is very difficult to establish a causative role
for the gut microbiome in the health effects of prebiotics
(104), partly because of differences among individuals to
prebiotic treatments in the microbiome ecosystem (94, 102) and
heterogeneity in host functional outcomes that were measured
[e.g., number of bowel movements per day (55, 89, 94, 95,
105)] and the possibility that health effects of dietary fibers and
prebiotics are microbiome independent (106).
Probiotic Administration
A stable temporal core of species constitutes the majority
(>75%) of the microbial community (73, 107), and these are
not easily displaced (94, 108). In a study characterizing the
effect of a Lactobacillus rhamnosus GG (LGG) intervention
that achieved average fecal LGG counts 1000-fold higher than
in the placebo group, the intervention was highly variable
among individuals, did not alter the temporal stability of the
microbiota, and did not correlate with changes in individual
host functional measures [i.e., serum lipids (109)]. A systematic
review of 7 randomized controlled trials testing the effects
of administering probiotics to healthy adults did not find
significant changes in fecal microbiota composition compared
with control in any of the studies (110). Higher doses of
multispecies probiotic formulations (70 billion CFU/d) seem to
be necessary to achieve earlier, higher, and longer recovery in
the feces (111). Persistence of probiotic strains in the human
gut, in most studies, is temporal (only a few days) (112–
115). When probiotics were administered as capsules, yogurt,
or cheese, there was no effect on clinical chemistry (serum
cholesterol, HDL, LDL, triglycerides, ALAT, ASAT, C-reactive
protein, hemoglobin) or the composition of gut microbiota
(51). However, one has to consider that probiotic strains
are for the most part selected based on technological and
not ecological criteria, and most probiotic strains belong to
bacterial species that are not core members of the human
microbiome (116). If an autochthonous core member of the gut
microbiota is used (Bifidobacterium longum AH1206), stable
persistence can be achieved for 6 mo after daily oral dosing
but only in ∼30% of individuals (67). Baseline resident fecal
B. longum abundance was inversely associated with B. longum
AH1206 persistence, possibly because indigenous organisms
blocked the nutritional niche for the incoming probiotic
(67). Thus, resident microorganisms of the gut microbiota
may outcompete ingested probiotic strains (94). The lack of
impact of probiotics on gut microbiota composition can be
explained using ecological principles. The gut microbiota is
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FIGURE 2 Successful invasion of an orally administered probiotic is a multistage process. Adapted with permission from Walter et al. (116).
highly resistant to incoming microbes, a trait referred to as
“colonization resistance” (117). To become established, the
incoming bacterial species must be able to overcome habitat
filters in the gut and successfully compete for resources with
the resident microbiota (116) (Figure 2). Even if engraftment
is achieved, the probiotic strain has to engage in ecological
interactions with the microbiota to alter the community. When
studies with probiotics have not altered the gut microbiota,
it might be due to a failure to consider ecological criteria in
strain selection, production, and application, leading to strains
being used that lack adaptations to the human gastrointestinal
tract (116). However, it is important to consider that probiotics
may improve health without changing the gut microbiota (e.g.,
by direct immunological, metabolic, and neurological effects
on the host or by affecting the function of the commensal
gut microbes). Consistent with this concept, data suggest that
LGG may influence the function of other members of the
gut microbiota (118). In this clinical trial in healthy adults,
LGG did not alter the composition of the gut microbiota but
did modulate its transcriptional profile in a subset of subjects.
Expression of genes involved in flagellar motility, chemotaxis,
and adhesion from Bifidobacterium and the dominant butyrate
producers, Roseburia and Eubacterium, were increased during
probiotic consumption in this cohort, suggesting that LGGmay
influence the activity of certain beneficial commensal bacteria
and, thereby, indirectly affect host physiology.
Technical Challenges in Studying Gut
Microbiome and Host Interactions
Measuring the human microbiome requires proper sample
acquisition, handling, storage, and analysis. Procedures and
analytical methods need to be reproducible and consistently
applied across studies and populations to obtain accurate diet
and dietary intake assessments (119, 120) and to minimize
technical variation in metagenomic data (73, 121, 122). For
the most part, samples are obtained from defecated stools
(122). Before genetic sequencing, each physical, chemical, and
biological step involved in the molecular analysis of a microbial
sample can be a source of bias, which could lead to a distorted
perspective of the “real” microbiome (123). When extracting
microbial nucleotides (DNA and/or RNA), microbial proteins,
or microbial metabolites, each step can induce species-specific
bias (124–126). DNA extraction is a common source of
variation among laboratories (73, 127), partially because Gram-
positive bacteria cell walls are more difficult to lyse.
As suggested (27), there is a need to focus on establishing
causation and molecular mechanism with an emphasis on
phenotypes that are large in magnitude, easy to measure, and
unambiguously driven by the microbiota to ultimately identify
the health and disease implications to humans. Such informa-
tion is difficult if not impossible to obtain in sequencing surveys,
which can only establish associations between microbiome
features with host function or disease risk but not assign
causation or directionality. Even if such associations are found,
they are often not consistent among studies because of a lack
of consistent sampling protocols and standards in microbiome
research (46). It is currently difficult to integrate microbiome
research findings into large databases in a meaningful manner
because of the diversity of data and sample collection processes,
sequencing, and bioinformatic protocols being used within
research communities. There is a need for consensus and
the adoption of standardized experimental and computational
methods across studies and populations to minimize technical
artifacts.
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Regulatory Considerations with Respect
to the Gut Microbiome
With an expanding body of microbiome-related research that
is stimulating widespread interest in prebiotics and probiotics,
regulatory agencies are increasingly confronted with proposals
for health claims relating to the effects of diet on the gut
microbiota. Permissible claims for the purpose of food labeling
vary widely across the globe, although product labels and
claims are expected everywhere to be accurate, truthful, and
not misleading. The Codex Alimentarius Commission (Codex)
publishes standards for voluntary adoption by any country.
Codex has published general guidelines on nutrition labeling
based on 2 types of nutrient reference values (NRV): 1) NRV-
Requirements (NRV-R) based on levels of nutrients associated
with nutrient requirements and 2) NRV-Noncommunicable
Disease (NRV-NCD) based on levels of nutrients associated
with reduction in the risk of diet-related noncommunicable
diseases not including deficiency diseases or disorders (128).
However, individual countries are left to develop guidance
for specific foods and ingredients as they deem appropriate,
including claims (129) that might relate to effects on the
gut microbiome. The extent to which international regulatory
bodies have addressed the latter varies widely.
Regulatory considerations in the United States,
Canada, and Europe
In the United States, nutrition-related claims made in labeling
are regulated through the Federal Food, Drug and Cosmetic
Act, as amended (130). Within these regulations, nutrition-
related claims consist of 4 types: 1) nutrient content claims,
2) structure-function claims, 3) health claims, and 4) dietary
guidance claims (131–133). In Canada, nutrition-related claims
consist of 1) nutrient content claims and 2) health claims, which
are regulated through the Food and Drugs Act (134). In Europe,
1) nutrition and 2) health claims are options for food labeling
(135).
Nutrient declarations
Nutrient declarations describe the amount of a nutrient in a
food product, thereby characterizing the nutrient profile of a
food. In these regions, regulations mandate the nutrients that
must be presented on a label and the format of the label.
Reference values for labeling purposes have been established by
Codex (percent NRV), United States and Canada (percent Daily
Value), and the European Union [EU; percent Reference Intake]
and are usually based on authoritative evaluations of nutrient
requirements for the generally health population (e.g., DRIs in
the United States). In the United States and Canada, claims that
a food is a good or excellent source of a nutrient require the
establishment of a reference value for labeling purposes and are
authorized through regulations (131, 132, 136). Similarly, the
EU regulates nutrient claims and lists them in the annex of the
Claims-Regulation (EU Directive 1924/2006).
In the United States and Canada, statements can be made for
a dietary ingredient that does not have an established reference
value (e.g., 240 mg DHA per serving, 12 mg lutein per serving,
or 1 million CFU Lactobacillus acidophilus) per serving, but
these statements must include the substance and the amount
and not imply that the product is a good or excellent source
of the substance (131, 136). The EU provides an option to
make claims for “other nutrients” when added in a “significant
amount,” a term that is not well defined by the regulation, and
each proposed claim must be evaluated on a case-by-case basis.
For example, “containing Lactobacillus acidophilus” might be
a possible claim in the EU.
Labeling regulations specific to some dietary fibers
and prebiotics
Before a manufacturer can add and label an isolated or synthetic
nondigestible carbohydrate as “dietary fiber”on a food product
in the United States or Canada, US (137) and Canada (132)
regulations require demonstration of “a physiological effect that
is beneficial to human health.” These regulations are relevant
when considering labeling a prebiotic. The FDA and Health
Canada have published lists of dietary fibers that have been
assessed and found acceptable as fiber sources (Table 1) (137,
138). If a synthetic or isolated nondigestible carbohydrate is not
listed, a petition must be submitted requesting a review of the
evidence of a physiological effect that is beneficial to human
health. Examples of physiological effects that are beneficial to
human health by the FDA and Health Canada are presented
in Table 2 (139, 140). These lists do not include any reference
to a “healthy gut microbiome.”
Structure-function and function claims
A structure-function (United States) or function (Canada and
EU) claim is any statement linking the beneficial effects of a food
or dietary ingredient with the normal functioning or biological
activities of the body (e.g., dietary fiber to help maintain the
health of the gastrointestinal tract). These claims cannot refer
to a disease state or a reduction in disease risk (131, 141). In
the United States and Canada, when requested by regulatory
agencies, manufacturers must produce scientific substantiation
describing the expected effect or benefit of the nutrient or
ingredient and study design, and it must reflect the totality
of the evidence (77, 142). In Europe, function claims must be
authorized before they can be used (135).
Disease risk reduction claims
A disease risk reduction claim is any statement linking the
consumption of a food or constituent of food with a reduction
in risk of developing a diet-related disease or condition.
Regulatory agencies in the United States, Canada, and Europe
authorize disease risk reduction claims that are supported
by significant scientific agreement (142–144). In Canada,
premarket review and approval of claims about diseases or
health conditions not listed in Schedule A to the Food andDrugs
Act are voluntary (133).
To date, disease risk reduction claims have been authorized
for fiber-containing foods and reduced risk of some types of
cancer as well as foods that contain fiber (with emphasis on
soluble fiber) from certain foods and reduced risk of coronary
heart disease (144, 145). In 2009, Canada approved nonspecies-
specific claims for probiotics in foods with a restricted list of
species (146), but none relate to the gut microbiome. In the
United States, guidance was issued on the types of studies from
which the FDA can draw conclusions for evaluating health
claims (147), but neither the FDA or Canada has approved
any microbiome-specific claims for foods containing prebiotics.
The EU-issued draft guidance specifically related to gut and
immune function and the characterization of claims referencing
a “beneficial physiological effect” and disease reduction (148).
Regulatory considerations in Asia and other regions
Claims related to the gut microbiome are more common outside
of the United States, Canada, and Europe. In the Southeast
Asia region, several examples of claims can be found (Table 3)
(149–156).
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TABLE 1 Lists of Isolated or Synthetic Nondigestible Carbohydrates Meeting the “Dietary Fiber” Definition in the United States and
Canada
United States (137) Canada (138)
• β-glucan soluble fiber
• Psyllium husk
• Cellulose
• Guar gum
• Pectin
• Locust bean gum
• Hydroxymethylpropylcellulose
• Mixed plant cell wall fibers (a broad category that includes fibers like sugar
cane fiber and apple fiber, among many others)
• Arabinoxylan
• Alginate
• Inulin and inulin-type fructans
• High-amylose starch (resistant starch 2)
• Galactooligosaccharide
• Polydextrose
• Resistant maltodextrin/dextrin
• Acacia gum or gum arabic
• Barley β-glucan concentrate
• Brans (barley, corn, oat, wheat)
• Fructooligosaccharides or oligofructose
• Galactooligosaccharides
• Inulin from chicory root, Jerusalem artichoke tuber, blue agave head
• Isomaltooligosaccharides
• Oat β-glucan concentrate
• Oat hull fiber
• Partially hydrolyzed guar gum
• Pea hull fiber
• Peel (apple, blueberry, cranberry, orange)
• Pulp (orange, tomato)
• Polydextrose
• Polysaccharide complex (glucomannan, xanthan gum, sodium alginate)
• Maltodextrin
• Resistant starches
• Syrup (fiber)
• Wheat flakes
• Whole or edible parts of traditional fruits, vegetables, cereals, legumes, nuts, and seeds
Japan regulates health-related claims for food as “Food for
Specified Health Uses”and “Food with Function Claims” (157).
Health claims for gut microbiome can be declared under those
regulatory systems with the required evidence support (150,
158, 159). Table 3 contains example claims from Japan and
other Asian regions.
Brazil is developing a technical dossier for the approval of
new probiotic products. As of February 2019, the draft concept
is to include 2 types of claims. The first are general claims, which
are specific to a “general function” benefit of the probiotic
in the body. An example would be “better gastrointestinal
health,” which could include outcomes such as improvements
in intestinal transit time or reduced abdominal pain. The
second are specific claims, which include benefits related to a
physiologic or metabolic function. Studies supporting all types
of proposed claims must be conducted in humans and may
include systematic reviews, meta-analyses, randomized clinical
studies, and prospective cohort studies. Benefits must be strain
related (160).
What Type of Information Is Needed to
Define a Healthy Gut Microbiome?
Despite the importance of the gut microbiota and diet-
microbiome interactions for human health, North Ameri-
can and European regulatory agencies have not approved
microbiome-specific health claims. This is likely due to the in-
herent challenges and complexities that surround the definition
of a healthy microbiome and a lack of validated biomarkers or
surrogate end points to define and measure microbiome-host
interactions. For regulatory agencies to evaluate and enforce
claims related to the microbiome and its impact on host health,
critical information is necessary that requires a comprehensive,
multidisciplinary research agenda. In addition to existing
data, prospective and cohort studies are needed to elucidate
relationships between the gutmicrobiome (species and function)
and biomarkers or surrogate end points in the host that are
accepted indicators of normal biological processes, pathogenic
processes, or responses to an exposure or intervention, including
therapeutic interventions (161), regardless of structure (gut
epithelium, immune system, etc.) or biological sample (blood,
feces, saliva, urine, etc.). Just as biomarkers have been identified
and validated as surrogate end points for cardiovascular disease
and diabetes (162), similar efforts are needed for the gut
microbiome and host responses to the gut microbiome.
To identify such “microbiome biomarkers,” prospective
studies are needed in well-characterized human populations
to determine features (microbiota diversity, specific taxa,
metabolic processes, gene clusters, metabolites, etc.) that
predict disease risk or serve as surrogate markers of dis-
ease. Once such potential “biomarkers” have been identified,
randomized, placebo-controlled clinical trials using a variety
of microbiome-modulating strategies (probiotics, prebiotics,
TABLE 2 Examples from the United States and Canada of Physiological Effects of Nondigestible Carbohydrates That Are
Considered Beneficial to Human Health
United States (139) Canada (140)
• Lowering blood glucose and cholesterol levels
• Lowering blood pressure
• Increase in frequency of bowel movements (improved laxation)
• Increased mineral absorption in the intestinal tract
• Reduced energy intake (e.g., due to the fiber promoting a feeling of fullness)
• Improves laxation or regularity by increasing stool bulk
• Reduces blood total and/or LDL cholesterol levels
• Reduces postprandial blood glucose and/or insulin levels or increases sensitivity to insulin
• Provides energy-yielding metabolites through colonic fermentation
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TABLE 3 Approved Claims in Asia and Other Pacific Regions
Indonesia (149)
• Soluble dietary fiber (psyllium, β-glucan from oats, inulin from chicory, and pectin from fruit) can help maintain/preserve the function of the digestive tract.
Japan (150–152)
• Bowel regulation by Bifidobacterium longum BB536
• lb81 lactic acid bacteria help balance the intestinal bacteria and keep the condition of the stomach maintained.
• Both galactooligosaccharides and dietary fiber work together to increase intestinal bifidobacteria and lactic acid bacteria and adjust the condition of the stomach.
• Live Bifidobacterium (Bifidobacterium lactis bb-12) help improves the intestinal environment and keep the condition of the stomach maintained.
Malaysia (154)
• Inulin and oligofructose (fructooligosaccharide):
◦ Inulin helps increase intestinal bifidobacterial and helps maintain a good intestinal environment.
◦ Oligofructose (fructooligosaccharide) helps increase intestinal bifidobacterial and helps maintain a good intestinal environment.
◦ Inulin is bifidogenic.
◦ Oligofructose (fructooligosaccharide) is bifidogenic.
◦ Inulin is prebiotic.
◦ Oligofructose (fructooligosaccharide) is prebiotic.
• High-amylose maize resistant starch helps improve/promote colonic/bowel/intestinal function/environment.
• Bifidobacterium lactis helps improve a beneficial intestinal microflora.
• Oligosaccharide mixture containing 90% (wt/wt) galactooligosaccharides and 10% (wt/wt) long-chain fructooligosaccharides:
◦ The above oligosaccharide mixture is prebiotic.
◦ The above oligosaccharide mixture is bifidogenic.
◦ The above oligosaccharide mixture increases intestinal bifidobacteria and helps maintain a good intestinal environment.
• Polydextrose:
◦ Polydextrose is bifidogenic.
◦ Polydextrose helps increase intestinal bifidobacteria and helps maintain a good intestinal microflora.
Singapore (155)
• Inulin:
◦ Inulin helps support growth or beneficial bacteria/good intestinal flora in gut.
◦ Inulin helps increase intestinal bifidobacteria and helps maintain a good intestinal environment.
• Oligofructose stimulates the bifidobacteria, resulting in a significant increase of the beneficial bifidobacteria and the presence of less-desirable bacteria is reduced.
• Prebiotic promotes the growth of good Bifidus bacteria to help maintain a healthy digestive system.
• Probiotics
◦ Probiotics help maintain a healthy digestive system.
◦ Probiotics help in digestion.
◦ Probiotics help to maintain a desirable balance of beneficial bacterial in the digestive system.
◦ Probiotics help to suppress/fight harmful bacteria in the digestive system, thereby helping to maintain a healthy digestive system.
Thailand (154, 156)
• Gut health/function claims have not been approved.
synbiotics, dietary fiber, and fecal microbiota transplantation)
should be tested to understand mechanistic relationships
between the gut microbiome and host health (163). By
combining multiomics characterization of microbiome with
measures of host metabolome, associations can be elucidated
that at least infer causation (which is extremely hard to
establish). Both the identification of microbiome biomarkers
and their validation are complicated due to the substantial
variability of the microbial communities and the complex
ecological factors that cause it. Studies therefore need to be
well designed and conducted with adequate sample sizes among
specific and well-defined populations to understand the roles
of age, sex, life stage (pregnancy, lactating, menopausal stage),
obesity, chronic disease, diet, human behavior (use of alcohol,
antibiotics, tobacco), geography, environment (urban, rural),
socioeconomic status, ethnicity, and pattern of immigration.
Such studies should include detailed dietary data to help
elucidate confounders, such as the impact of amount and
types of nondigestible carbohydrates consumed, local compared
with nonlocal foods, organic compared with nonorganic foods,
pesticide exposure, alcohol use, and water quality on the
microbiome.
Consensus should also be achieved regarding mandatory
baseline and follow-up data collection (biological samples, di-
etary data, health information, etc.), and processing of samples
(collections, analysis, interpretation, and data analysis) should
be standardized to understand microbiome-host relationships
and allowmicrobiome studies to be compared and/or combined.
What Are Current Limitations to
Establishing a Healthy Gut
Microbiome-Host Relationship?
Researchers in the gut microbiome field are faced with a daunt-
ing complexity when trying to define a healthy gut microbiome
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TABLE 4 Workshop Summary
• Causality has not been established between changes in gut microbiome structure and function and markers of human health.
• It is not established if dysbiosis is a cause, consequence, or both of changes in human gut epithelial function and disease.
• Microbiome communities are highly individualized, show a high degree of interindividual variation to perturbation, and tend to be stable over years.
• The complexity of microbiome-host interactions requires a comprehensive, multidisciplinary research agenda to elucidate relationships between gut microbiome and host health.
• Biomarkers and/or surrogate indicators of host function and pathogenic processes based on the microbiome need to be determined, along with normal ranges, and validated.
• Future studies measuring responses to an exposure or intervention need to combine validated microbiome-related biomarkers and surrogate indicators with multiomics
characterization of the microbiome.
• Because of human gut microbiome dynamics, static genetic sampling misses important short- and long-term microbiome-related changes to host health, so future studies should be
powered to account for inter- and intraindividual variation and should use repeated measures within individuals.
interrelationship. As an ecological community, the microbiome
is structured by hundreds of genetic, environmental, and clinical
factors and likely by stochastic ecological processes, driving
vast interindividual variation and biogeographic differences
in human populations (39, 40, 164). All this complicates the
identification of microbiome features that determine health. In
addition, microbiome features might influence risk of disease
years if not decades before pathologies arise.Neither cause-and-
effect relationships nor the molecular mechanisms are currently
sufficiently understood (27). Without this information, it will
be difficult to make progress on what constitutes a healthy
gut microbiome and translate this information into tangible
nutritional or pharmaceutical strategies and regulatory policies.
What Types of Studies Can Address
These Gaps?
Because of the dynamics of the human gut microbiome, static
genetic sampling misses important short-term and long-term
microbiome-related changes to host health. Future studies
need to be conducted in larger human populations to address
interindividual variability and use repeated measures within
individuals to help overcome intraindividual variability.
Multicenter comparative studies and workshops are needed
to develop best practices for microbiome-host health studies.
Research is needed to develop standards for the collection of
dietary information, subject demographics, biological samples
(timing, frequency, site), laboratory processing, genetic analyses,
and data manipulation/analysis. Based on these findings,
metabolomic indices in blood, feces, and urine and host-specific
indicators of health should be identified, validated, and agreed
on so that forthcoming consensus statements can be used
to guide regulatory agencies. Large prospective and cohort
studies measuring lifestyle (diet, culture, antibiotic use) effects in
diverse populations (age, sex, life stage, disease, socioeconomic
status, education, geography) on the microbiome, measuring
both microbiome characteristics and metabolic functions of the
microbiome and host and systematically linking them to disease
risk, are needed to elucidate microbiome-host relationships.
More hypothesis-driven clinical research is needed targeting
microbiome traits to determine causality between microbiome
structure/functional changes and validated surrogate markers
of host function, host physiology/function, and health. As
suggested by Fischbach (27), this research agenda should focus
on establishing causation and molecular mechanisms, with an
emphasis on phenotypes that are large in magnitude, easy to
measure, and unambiguously driven by the microbiota. If such
studies are conducted in an equivalent way to studies that
established the validity of clinical markers of human disease,
it might be possible to determine what constitutes a healthy
microbiome in the future.
Future Considerations
At present, a mechanistic understanding of the host-microbiome
relationship is lacking, and there is a need for more research
(Table 4).
To determine what constitutes a healthy microbiome,
research needs to be conducted with repeated measures within
the same individuals to establish mechanistic links between
specific microbiome features (diversity, specific taxa, gene
clusters, metabolites, etc.) and either function or biomarker or
surrogate end point, equivalent to the establishment of LDL
cholesterol for cardiovascular disease, glycosylated hemoglobin
for diabetes mellitus, or blood pressure for cardiovascular
disease. Because of high interindividual variability of the human
microbiome, it will be extremely complicated and might even
be impossible to identify and validate features of the human
microbiome and normal ranges that can be used to predict
human health or disease risk.
With the establishment of “microbiome features” that
correlate with host function, biomarker, or surrogate end point,
it will be possible to devise microbiome-targeted strategies to
modulate host indicators of health and possibly decrease disease
risk. Just as statins have been tested for efficacy in reducing
elevated cholesterol levels to reduce cardiovascular disease risk
(165), it should be possible to test efficacy of interventions with
probiotics, prebiotics, synbiotics (a combination of probiotics
and prebiotics in the same food product), dietary fiber,
and FMTs on microbiome features and human health. This
will require placebo-controlled human clinical trials in an
appropriate target population. Such trials should be performed
using an ecological and evolutionary perspective (116) and
adequately powered to account for interindividual variation
and allow for analysis of subpopulations. Also, given the
immense individuality of the gut microbiome, efforts should
determine the value of personalizing microbiome-targeted
approaches.
Microbiomes are assembled by ecological processes that
are complex and often stochastic, and most important, the
microbial traits that determine how microbiomes assemble are
likely not the same traits that determine health.
Health effects of specific microbiome features might well
be context dependent, and bacterial taxa being associated with
health in one disease setting and disease in another have already
been reported. Akkermansia, for example, is correlated with
healthier metabolic features in obese individuals (166, 167)
and inversely with prevalence of multiple sclerosis (168, 169).
It might therefore be impossible to determine microbiome
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features that are universally healthy; what constitutes a “healthy
microbiome” for one person or human population might well
be unhealthy in a different context. For example, a microbiome
that contributes to weight gain would be detrimental in an
obesogenic environment but would be beneficial during food
deprivation. As reviewed above, other factors, such as birth
route, antibiotic use, and first diet (breast milk, formula feeding,
etc.), may also reduce microbiome diversity, induce detrimental
metabolic processes by the microbiota, and contribute to
noncommunicable disease risk. It is possible that a progressive
deterioration of the human microbiota, attributable to an
industrialized lifestyle, is associated with a societywide dysbiosis
that is not confined to only a few individuals (170), making
it very difficult to characterize features specific to a “healthy
gut microbiome.” Rather than trying to define a “healthy”
microbiome, future research efforts should determine environ-
mental, clinical, and nutritional factors that decrease symbiotic
attributes of the gut microbiome in different societal contexts.
In conclusion, microbiome communities are known to
be highly individualized, tend to be stable for years, and
show a high degree of interindividual variation. Redundancy
in microbiome features is common, and diversity is likely
more important than the presence of specific taxa. Ecosystem
functions are probably more important than specific individual
members (which may even show functional redundancy). As
efforts continue to define a “healthy microbiome,” it may be
helpful to paraphrase the words of Curtis Huttenhower: “In
a forest, a single tree species needn’t be present for a forest
to be considered ‘healthy’ (even if many do). The presence of
every tree species isn’t a requirement for a forest to be ‘healthy’.
Not every ‘healthy’ forest occurs in a typical forest environment
(even if many do).”
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